Complete Filing Data
Ocean Biomedical, Inc. reported Stockholders Equity of -$96.26 million for FY2024.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Ocean Biomedical, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Net Income Loss | -$9.5M | -$114.5M | -$17.4M |
| Operating Income Loss | -$3.8M | -$10.2M | -$16.1M |
| Nonoperating Income Expense | -$5.7M | -$104.3M | -$1.2M |
| Operating Expenses | $3.8M | $10.2M | $16.1M |
| General And Administrative Expense | $3.8M | $9.5M | $7.7M |
| Research And Development Expense | $26.0K | $709.0K | $8.4M |
| Interest Income Expense Net | -$2.0M | -$1.8M | -$1.2M |
| Other Nonoperating Income Expense | -$1.0K | $5.0K | |
| Noncash Interest Expense | $762.0K | $929.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Loss | -$8.2M | -$3.7M | -$17.2M | $13.0M | -$14.1M | -$11.4M | -$72.1M | -$3.7M | -$7.3M | -$5.4M | -$42.5K | -$82.00 |
| Operating Income Loss | -$958.0K | -$768.0K | -$682.0K | -$595.0K | -$2.7M | -$2.8M | -$5.4M | -$3.2M | -$6.9M | -$5.1M | -$42.7K | -$82.00 |
| Nonoperating Income Expense | -$7.3M | -$2.9M | -$16.6M | $13.6M | -$11.4M | -$8.6M | -$66.7M | -$495.0K | -$433.0K | -$265.0K | ||
| Operating Expenses | $958.0K | $768.0K | $682.0K | $595.0K | $2.7M | $2.8M | $5.4M | $3.2M | $6.9M | $5.1M | $42.7K | |
| General And Administrative Expense | $940.0K | $768.0K | $682.0K | $569.0K | $2.4M | $2.8M | $5.0M | $1.3M | $3.7M | $1.9M | ||
| Research And Development Expense | $18.0K | $26.0K | $305.0K | $28.0K | $393.0K | $1.9M | $3.2M | $3.2M | ||||
| Interest Income Expense Net | -$461.0K | -$515.0K | -$637.0K | -$293.0K | -$668.0K | -$301.0K | -$61.0K | -$49.0K | -$266.0K | |||
| Other Nonoperating Income Expense | -$3.0K | -$1.0K | $1.0K | |||||||||
| Noncash Interest Expense | $301.0K | $24.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Stockholders Equity | -$96.3M | -$10.8M | -$6.7M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $34.0K | $60.0K | ||
| Retained Earnings Accumulated Deficit | -$204.0M | -$196.1M | -$81.6M | -$564.1K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$780.0K | $970.0K | -$26.0K | |
| Liabilities Current | $31.8M | $30.0M | $12.7M | $246.4K |
| Liabilities And Stockholders Equity | $5.5M | $1.8M | $108.7M | |
| Assets Current | $2.1M | $1.8M | $1.5M | |
| Assets | $5.5M | $1.8M | $108.7M | |
| Accounts Payable Current | $16.2M | $11.4M | $34.4K | |
| Liabilities | $97.4M | $96.3M | $12.7M | $3.4M |
| Accrued Liabilities Current | $946.0K | $445.0K | $212.0K | |
| Gains Losses On Extinguishment Of Debt | -$15.1M | |||
| Deferred Underwriting Commissions | $3.2M | $3.2M | ||
| Deferred Offering Costs | $1.8M | |||
| Restricted Cash Current | $1.0M | |||
| Loans Payable Current | $12.1M | $776.0K | ||
| Repayments Of Short Term Debt | $2.1M | |||
| Backstop Put Option Liability | $58.5M | |||
| Temporary Equity Value Excluding Additional Paid In Capital | $110.4M | $107.1M | ||
| Gain Loss In Connection With Backstop Put Option Liability And Fixed Maturity Consideration | ||||
| Derivative Liabilities Current | $1.7M | $764.0K | ||
| Cash And Marketable Securities Held In Trust Account | $110.4M | $107.1M | ||
| Loss In Connection With Backstop Put Option Liability And Fixed Maturity Consideration | $2.0M | $62.6M | ||
| Investments In Affiliates Subsidiaries Associates And Joint Ventures | $3.4M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | -$92.4M | -$97.6M | -$92.7M | -$75.8M | -$90.8M | -$75.2M | -$61.7M | -$54.8M | -$9.8M | -$9.5M | -$7.5M | -$1.3M | $24.9K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $777.0K | $224.0K | $240.0K | $229.0K | $519.0K | $1.0M | $1.0M | $2.2M | $306.0K | $116.0K | $395.0K | $292.0K | $1.2M | |
| Retained Earnings Accumulated Deficit | -$213.8M | -$205.5M | -$200.3M | -$183.1M | -$179.2M | -$162.0M | -$149.0M | -$2.3M | -$914.8K | -$729.8K | -$42.6K | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $553.0K | -$485.0K | $272.0K | $232.0K | $1.2M | |||||||||
| Liabilities Current | $26.6M | $33.9M | $30.7M | $30.1M | $30.9M | $26.7M | $23.4M | $2.1M | $506.0K | $102.2K | $9.9K | |||
| Liabilities And Stockholders Equity | $1.6M | $902.0K | $1.1M | $1.9M | $2.9M | $1.0M | $20.9M | $25.0M | $109.1M | $108.6M | $108.3M | $108.9M | ||
| Assets Current | $1.5M | $812.0K | $1.0M | $1.3M | $1.8M | $1.0M | $2.2M | $306.0K | $599.6K | $745.2K | $1.2M | $1.8M | ||
| Assets | $1.6M | $902.0K | $1.1M | $1.9M | $2.9M | $1.0M | $20.9M | $25.0M | $109.1M | $108.6M | $108.3M | $108.9M | ||
| Accounts Payable Current | $16.4M | $15.9M | $16.6M | $17.2M | $16.9M | $16.0M | $14.0M | $15.4M | $181.0K | $145.0K | $65.4K | $4.9K | ||
| Liabilities | $94.0M | $98.5M | $94.6M | $78.7M | $76.3M | $29.3M | $5.2M | $3.7M | $3.3M | $3.2M | ||||
| Accrued Liabilities Current | $804.0K | $764.0K | $927.0K | $860.1K | $361.0K | $36.7K | $5.0K | |||||||
| Gains Losses On Extinguishment Of Debt | -$224.0K | -$903.0K | -$14.0M | |||||||||||
| Deferred Underwriting Commissions | $3.2M | $3.2M | $3.2M | |||||||||||
| Deferred Offering Costs | ||||||||||||||
| Restricted Cash Current | $777.0K | $224.0K | $240.0K | $225.0K | $500.0K | $1.0M | $1.0M | |||||||
| Loans Payable Current | $9.4M | $16.3M | $12.8M | $11.0M | $9.9M | $12.1M | ||||||||
| Repayments Of Short Term Debt | $550.0K | |||||||||||||
| Backstop Put Option Liability | $61.4M | $59.1M | $57.0M | $55.9M | $42.9M | $41.6M | ||||||||
| Temporary Equity Value Excluding Additional Paid In Capital | $108.5M | $107.1M | $107.1M | $107.1M | ||||||||||
| Gain Loss In Connection With Backstop Put Option Liability And Fixed Maturity Consideration | -$2.8M | -$1.5M | -$13.3M | $15.3M | -$11.4M | -$2.7M | -$31.3M | |||||||
| Derivative Liabilities Current | $198.0K | $1.1M | $1.7M | $2.5M | ||||||||||
| Cash And Marketable Securities Held In Trust Account | $108.5M | $107.2M | $107.1M | $107.1M | ||||||||||
| Loss In Connection With Backstop Put Option Liability And Fixed Maturity Consideration | -$15.3M | $11.4M | $31.3M | |||||||||||
| Investments In Affiliates Subsidiaries Associates And Joint Ventures | $90.0K | $90.0K | $90.0K | $574.0K | $1.1M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$4.2M | -$9.4M | -$993.0K |
| Net Cash Provided By Used In Financing Activities | $3.4M | $10.4M | $967.0K |
| Employee Benefits And Share Based Compensation | $745.0K | $1.2M | $12.4M |
| Proceeds From Short Term Debt | $8.3M | $735.0K | |
| Increase Decrease In Accounts Payable And Accrued Liabilities | $869.0K | $1.2M | $2.8M |
| Increase Decrease In Accounts Payable Related Parties | -$343.0K | $467.0K | |
| Proceeds From Issuance Of Common Stock | $14.3M | ||
| Increase Decrease In Prepaid Expense | -$517.0K | $519.0K | -$384.6K |
| Proceeds From Effect Of Business Combination Net Of Issuance Costs | $52.1M | ||
| Payments Related To Tax Withholding For Share Based Compensation | $12.7M | ||
| Increase Decrease In Other Changes In Operating Assets And Liabilities | |||
| Increase Decrease In Accrued Liabilities | $1.1M | ||
| Increase Decrease In Accounts Payable | $290.4K | ||
| Net Cash Provided By Used In Investing Activities | -$2.1M | ||
| Share Based Compensation |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$356.0K | -$485.0K | -$2.7M | -$367.0K | -$707.8K | $40.2K |
| Net Cash Provided By Used In Financing Activities | $909.0K | $2.9M | $599.0K | $109.0M | -$40.2K | |
| Employee Benefits And Share Based Compensation | $646.0K | $4.5M | ||||
| Proceeds From Short Term Debt | $909.0K | $1.4M | $599.0K | |||
| Increase Decrease In Accounts Payable And Accrued Liabilities | $854.0K | $766.0K | $1.6M | -$996.0K | ||
| Increase Decrease In Accounts Payable Related Parties | $32.0K | -$30.0K | $482.0K | |||
| Proceeds From Issuance Of Common Stock | $14.3M | |||||
| Increase Decrease In Prepaid Expense | $127.0K | $175.0K | $670.9K | |||
| Proceeds From Effect Of Business Combination Net Of Issuance Costs | $52.1M | |||||
| Payments Related To Tax Withholding For Share Based Compensation | $12.7M | |||||
| Increase Decrease In Other Changes In Operating Assets And Liabilities | $1.2M | |||||
| Increase Decrease In Accrued Liabilities | -$175.3K | $5.0K | $64.8K | |||
| Increase Decrease In Accounts Payable | $31.0K | $4.9K | $494.00 | |||
| Net Cash Provided By Used In Investing Activities | -$107.1M | |||||
| Share Based Compensation | $186.0K | $186.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Diluted EPS * | -$0.34 | -$4.35 | -$0.74 | |
| Earnings Per Share Basic | $-0.34 | $-4.35 | $-0.74 | |
| Weighted Average Number Of Shares Outstanding Basic | 27.5M | 26.3M | 23.4M | |
| Common Stock Shares Issued | 34.6M | 23.4M | ||
| Common Stock Shares Outstanding | 34.6M | 23.4M | ||
| Common Stock Shares Authorized | 300.0M | 180.6M | ||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | ||
| Weighted Average Number Of Diluted Shares Outstanding | 27.5M | 26.3M | 23.4M | |
| Preferred Stock Shares Outstanding | 0.00 | |||
| Preferred Stock Shares Issued | 0.00 | |||
| Preferred Stock Shares Authorized | 1.3M | |||
| Preferred Stock Par Or Stated Value Per Share | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.09 | -$0.13 | -$0.63 | $0.48 | -$0.53 | -$0.43 | -$2.90 | -$0.16 | -$0.31 | -$0.02 | |||
| Earnings Per Share Basic | $-0.09 | $-0.13 | $-0.63 | $0.48 | $-0.53 | $-0.43 | $-2.90 | $-0.16 | $-0.31 | $-0.23 | |||
| Weighted Average Number Of Shares Outstanding Basic | 91.0M | 27.5M | 27.5M | 27.3M | 26.6M | 26.5M | 24.8M | 23.4M | 23.4M | 23.4M | |||
| Common Stock Shares Issued | 166.0M | 34.9M | 34.9M | 34.9M | 34.8M | 34.1M | 34.0M | 33.8M | 23.4M | ||||
| Common Stock Shares Outstanding | 166.0M | 34.9M | 34.9M | 34.9M | 34.8M | 34.1M | 34.0M | 33.8M | |||||
| Common Stock Shares Authorized | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | |||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||
| Weighted Average Number Of Diluted Shares Outstanding | 91.0M | 27.5M | 27.5M | 27.3M | 26.6M | 26.5M | 24.8M | 23.4M | 23.4M | ||||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
| Preferred Stock Shares Authorized | 10.0M | 0.00 | 1.3M | 1.3M | 1.3M | 1.3M | |||||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $745.0K | $1.2M | $12.4M | |
| Additional Paid In Capital | $105.3M | $70.8M | -$1.3M | |
| Adjustments To Additional Paid In Capital Warrant Issued | $2.3M | $825.0K | ||
| Transaction Costs | $356.0K | $8.7M | ||
| Prepaid Expense Current | $1.1M | $89.7K | $474.3K | |
| Stock Issued During Period Value New Issues | $1.8M | $676.0K | ||
| Other Income | ||||
| Derivative Gain Loss On Derivative Net | -$1.5M | $1.2M | ||
| Stock Issued During Period Value Issued For Services | $87.0K | $83.0K | ||
| Offering Costs Not Yet Paid | $2.0M | $1.8M | ||
| Stock Redeemed Or Called During Period Value | $52.1M | |||
| Stock Issued During Period Value Related To Short Term Loans | $1.6M | |||
| Stock Issued During Period Value Other | $13.6M | |||
| Formation And Operating Costs | $2.5M | |||
| Fixed Maturity Consideration | $4.1M | |||
| Business Combination Acquisition Related Costs | $7.6M | |||
| Short Term Loans Net Of Issuance Costs | ||||
| Noncash Stock Issuances | $667.0K | |||
| Interest Income Other | $1.5M | |||
| Fair Value Of Noncash Stock Issuances | $740.0K | |||
| Stock Issued During Period Value Adjustment To The Adjustedbalance | -$6.7M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $186.0K | $186.0K | $187.0K | $186.0K | $186.0K | $186.0K | $646.0K | $2.9M | $4.9M | $4.5K | ||||
| Additional Paid In Capital | $121.4M | $107.9M | $107.7M | $107.5M | $107.3M | $104.0M | $153.6M | $150.5M | -$2.3M | -$1.3M | -$1.3M | -$1.3M | ||
| Adjustments To Additional Paid In Capital Warrant Issued | $1.4M | $884.0K | $435.0K | $389.0K | $5.4M | |||||||||
| Transaction Costs | $73.0K | -$149.0K | $1.2M | $7.6M | ||||||||||
| Prepaid Expense Current | $715.0K | $588.0K | $802.0K | $1.0M | $1.3M | $127.5K | $168.5K | $349.6K | $670.9K | |||||
| Stock Issued During Period Value New Issues | $1.8M | $494.0K | $105.0M | |||||||||||
| Other Income | -$1.0K | -$1.0K | $5.0K | $1.0K | ||||||||||
| Derivative Gain Loss On Derivative Net | $269.0K | -$44.0K | -$331.0K | -$1.0M | $570.0K | -$1.2M | ||||||||
| Stock Issued During Period Value Issued For Services | $87.0K | $83.0K | $25.0K | |||||||||||
| Offering Costs Not Yet Paid | $2.0M | $2.0M | ||||||||||||
| Stock Redeemed Or Called During Period Value | $52.1M | |||||||||||||
| Stock Issued During Period Value Related To Short Term Loans | $334.0K | $903.0K | $358.0K | |||||||||||
| Stock Issued During Period Value Other | $13.6M | |||||||||||||
| Formation And Operating Costs | $1.4M | $325.2K | $172.6K | $42.7K | $82.00 | |||||||||
| Fixed Maturity Consideration | $6.0M | $5.6M | $5.2M | $4.8M | $4.4M | $3.8M | ||||||||
| Business Combination Acquisition Related Costs | $7.6M | |||||||||||||
| Short Term Loans Net Of Issuance Costs | $11.9M | $6.6M | $776.0K | |||||||||||
| Noncash Stock Issuances | $186.0K | $358.0K | ||||||||||||
| Interest Income Other | $351.8K | $140.3K | $6.9K | $173.00 | ||||||||||
| Fair Value Of Noncash Stock Issuances | $109.0K | $577.0K | ||||||||||||
| Stock Issued During Period Value Adjustment To The Adjustedbalance | -$10.8M |
Most recent annual filing with the SEC: April 8, 2025
Data sourced from SEC EDGAR public filings as of August 8, 2026.